Price (INR)28,235.55 Today's Change-214.65 / -0.75% Shares traded10.67k 1 Year change+9.94% Beta0.1036 Data delayed at least 15 minutes, as of Jan 14 2025 10:01 GMT. Find More Stocks Use our equities screener to discover other potential opportunities. Find Stocks Similar to ABBOTINDIAGo...
The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013....
Thanks Mike. Good morning, everyone and thank you for joining us. Today, we reported second quarter adjusted earnings per share of $1.08, which reflects an acceleration in the contribution from the underlying base business. Organic sales, excluded COVID testing, increased low double-digits for th...
expanding its presence in emerging markets. The same year, a plan was announced to purchase a unit of Piramal Healthcare for $3.8 billion, which would make Abbott the biggest pharmaceutical company in India.
Thanks, Scott. Good morning, everyone, and thank you for joining us. Today, I'll discuss our 2022 results as well as our outlook for this year. For the full-year 2022, we achieved ongoing earnings per share of $5.34, which is well above the original EPS guidance we set at the beginn...
Today we reported another highly successful year for Abbott during what’s been the single most disruptive healthcare event in our lifetimes. For the full year, we reported organic sales growth of nearly 10% and ongoing earnings per share of $3.65, which reflects double-digit growth and is at...
So the flip side of that is, competition is — you could potentially see I guess price as a lever to drive demand or to drive share capture. We’ve tried to focus every time we’re entering markets with a value proposition that sustains our pricing strategy and focus on the benefits tha...
Thanks, Scott. Good morning, everyone, and thank you for joining us. Today, we reported results of another strong quarter, including ongoing earnings per share of $1.15. Based on our performance through the first nine months of the year, we increased our full year adjusted earnings per share...
SHARE First and only minimally invasive, transcatheter treatment specifically approved for premature babies with patent ductus, a life-threatening opening in their heart (a common congenital defect) One-fifth of 240,000 children born in India with congenital heart de...
a non-employee director will receive one Abbott common share for each restricted stock unit. In addition, the restrictions on transfer were removed from the Abbott shares that had previously been issued under the program and from the shares of Hospira received as a dividend with respect to those...